You are here:

efavirenz (Sustiva)

Advice

following an abbreviated submission

efavirenz (Sustiva®) is accepted for use within NHS Scotland.

Indication under review: antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.

For patients at least 3 months old and weighing at least 3.5kg who cannot swallow capsules, the capsule contents can be administered with a small amount of food using the capsule sprinkle method of administration.

Efavirenz is listed in the British National Formulary for Children for the treatment of HIV infection.

Drug Details

Drug Name: efavirenz (Sustiva)
SMC Drug ID: 1125/15
Manufacturer: Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca
Indication: antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 7 December 2015

Back